Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
News Brief—Picking PIK3CD for Schizophrenia Treatment

30 July 2012. A new study published June 11 in Proceedings of the National Academy of Sciences plunges into the depths of neuregulin 1 (NRG1) signaling, and emerges with PIK3CD as a potential therapeutic target for schizophrenia. Amanda Law and colleagues at the National Institute for Mental Health in Bethesda, Maryland, probed the downstream workings of NRG1 and its receptor, ErbB4, which are involved in many cellular processes, including neural development and synaptic plasticity, and which have both been implicated in schizophrenia with genetic studies. As previously presented in 2011 at a New York Academy of Sciences meeting on Advancing Drug Discovery in Schizophrenia (see SRF related conference story), the team found signs of aberrant NRG1-ErbB4 signaling in schizophrenia, and reported that pharmacologically inhibiting a downstream protein encoded by PIK3CD blocks schizophrenia-related behaviors in rodents.

Drawing from human lymphoblastoid cell lines (LCLs) derived from patients with schizophrenia and controls, the researchers found an overabundance of an ErbB4 isoform, called CYT-1, in schizophrenia, and this isoform can bind to and activate phosphoinositide 3-kinase (PI3K). PIK3CD, which encodes a catalytic subunit of PI3K, was also elevated by 40 percent in schizophrenia compared to controls. Blocking PIK3CD might rectify this, and just such an inhibitor prevented amphetamine-induced locomotion in mice, and prepulse inhibition deficits in a rat model. Two family-based genetic studies also turned up single nucleotide polymorphisms in PIK3CD associated with schizophrenia. These and other data build a case for PIK3CD’s involvement in schizophrenia, which the authors suggest may offer a way to fine-tune NRG1-ErbB4 signaling without messing with the myriad other processes governed by the pathway.—Michele Solis.

Law AJ, Wang Y, Sei Y, O'Donnell P, Piantadosi P, Papaleo F, Straub RE, Huang W, Thomas CJ, Vakkalanka R, Besterman AD, Lipska BK, Hyde TM, Harrison PJ, Kleinman JE, Weinberger DR. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12165-70. Abstract

Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend the Primary Papers

Please note: A member needs to be both registered and logged in to submit a comment.


(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)


SRF News
SRF Comments
Text Size
Reset Text Size
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright